Quick answer
Can you take Wegovy with Fluoxetine (Prozac)? Generally compatible — no clinically significant interaction known.
- Severity
- none known
- Interaction type
- none
- Monitoring focus
- Routine mental health follow-up.
Always confirm with your prescriber. This is educational and based on FDA label data.
Key takeaways
- • Severity: No clinically significant interaction known.
- • Wegovy (weight management (FDA-approved obesity)) and Fluoxetine (Prozac) (SSRI (mental health)).
- • Clinical management: Continue as prescribed.
- • Monitoring: Routine mental health follow-up.
Mechanism
Fluoxetine has no clinically significant pharmacokinetic interaction with semaglutide. Both can cause nausea, particularly during initiation, but this is additive side effect overlap rather than a documented interaction.
Clinical management
Continue as prescribed.
GLP1Zoom does not prescribe medications or recommend dose changes. Always confirm any adjustment with your prescribing clinician before changing how you take Wegovy or Fluoxetine (Prozac).
Monitoring checklist
What to monitor + when to call your prescriber
Routine monitoring
- Routine mental health follow-up
Call prescriber urgently if
- worsening mood or new suicidal ideation
Deeper clinical context
Time course, adjustment scenarios, and subgroup considerations — for prescriber-led discussion. GLP1Zoom does not prescribe; defer to your clinician.
Time course
- Onset
- No PK interaction. Fluoxetine's long half-life (~4-6 days with norfluoxetine metabolite) makes overlap of side effects prolonged if either medication needs to be discontinued.
- Peak
- Side-effect overlap occurs during initial 4-6 weeks.
- Resolution
- If fluoxetine is discontinued, full washout takes 4-6 weeks due to long metabolite half-life.
Dose-adjustment scenarios
Generic clinical patterns prescribers commonly use. Your individual plan may differ.
Stable fluoxetine + new GLP-1
Similar to sertraline. No dose adjustments required. Stagger initiation timing if possible.
When to call your doctor
- worsening mood or new suicidal ideation
In emergencies — severe abdominal pain, persistent vomiting, fainting, signs of severe hypoglycemia (confusion, seizures), or signs of bleeding — call 911 or go to the nearest emergency department.
Source / FDA label citation
Not specifically listed as an interaction in current FDA label.
Editorial confidence: 7/10. Lower scores reflect inferred mechanism rather than directly-labeled interaction. We re-verify against the active FDA prescribing information at least every 6 months.
References
FDA Guidance for Industry: Clinical Drug Interaction Studies(2020)
GLP-1 Receptor Agonist Drug Interactions: Comprehensive Review (Diabetes Therapy)(2023)
DailyMed (NIH): FDA Prescribing Information Repository(2024)
Glucagon-Like Peptide-1 Receptor Agonists: Mechanisms and Clinical Use (Drucker, Cell Metabolism)(2018)
Tirzepatide GIP/GLP-1 Dual Agonism: Mechanism Review (Lancet Diabetes & Endocrinology)(2021)
GLP-1 Effects on Gastric Emptying: Pharmacology Review (American J Physiology)(2020)
Common questions
Can I take Fluoxetine (Prozac) with Wegovy?
Fluoxetine (Prozac) and Wegovy have no clinically significant interaction documented. Standard prescribing applies. Always confirm with your prescriber, since individual medical history can change the calculation.
What's the mechanism of any Wegovy + Fluoxetine (Prozac) interaction?
Fluoxetine has no clinically significant pharmacokinetic interaction with semaglutide. Both can cause nausea, particularly during initiation, but this is additive side effect overlap rather than a documented interaction.
What should I monitor when on Wegovy + Fluoxetine (Prozac)?
Routine mental health follow-up.
When should I call my doctor?
Contact your prescriber if you notice any of: worsening mood or new suicidal ideation.
Related
This page summarizes general pharmacology from FDA-approved prescribing information. It is not a substitute for personalized medical advice. GLP1Zoom is an affiliate-only comparator — we do not prescribe or sell medications. Full disclaimer.